



## Clinical trial results:

**A randomized, double-blind, placebo-controlled, multi-centre, sequential design, phase IIa study to evaluate safety and tolerability of epicardial injections of AZD8601 during coronary artery bypass grafting surgery**

### Summary

EudraCT number	2017-002690-19
Trial protocol	FI NL DE
Global end of trial date	23 July 2021

### Results information

Result version number	v2 (current)
This version publication date	24 July 2025
First version publication date	16 July 2022
Version creation reason	

### Trial information

#### Trial identification

Sponsor protocol code	D9150C00003
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	Astraalléen, Södertälje, Sweden,
Public contact	Global Clinical LEad, AstraZeneca, +1 18772409479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca, +1 18772409479, information.center@astrazeneca.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	23 July 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	23 July 2021
Global end of trial reached?	Yes
Global end of trial date	23 July 2021
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To investigate safety and tolerability of AZD8601 following epicardial injection in patients undergoing Coronary Artery Bypass Grafting (CABG) surgery with moderately impaired systolic function.

Protection of trial subjects:

This study was performed in compliance with International Council for Harmonisation (ICH) Good Clinical Practice, including the archiving of essential documents.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 February 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Finland: 8
Country: Number of subjects enrolled	Germany: 3
Worldwide total number of subjects	11
EEA total number of subjects	11

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	3
From 65 to 84 years	8
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at 4 clinical research centers in Finland and Germany First subject enrolled (First subject first visit/first consent signed date): 5 February 2017. Last subject last visit: 30 June 2020.

### Pre-assignment

Screening details:

This study was performed in compliance with International Council for Harmonisation (ICH) Good Clinical Practice, including the archiving of essential documents.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	AZD8601 3mg

Arm description:

AZD8601 3mg

Arm type	Experimental
Investigational medicinal product name	AZD8601
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Other use

Dosage and administration details:

Solution for epicardial injection

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Placebo

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection, Injection
Routes of administration	Other use

Dosage and administration details:

Solution for epicardial injection

<b>Number of subjects in period 1</b>	AZD8601 3mg	Placebo
Started	7	4
Completed	7	4

## Baseline characteristics

### Reporting groups

Reporting group title	AZD8601 3mg
Reporting group description: AZD8601 3mg	
Reporting group title	Placebo
Reporting group description: Placebo	

Reporting group values	AZD8601 3mg	Placebo	Total
Number of subjects	7	4	11
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	1	3
From 65-84 years	5	3	8
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	68.3	67.8	
standard deviation	± 5.8	± 10.8	-
Sex: Female, Male Units: Participants			
Female	0	2	2
Male	7	2	9
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	7	4	11
More than one race	0	0	0
Unknown or Not Reported	0	0	0

### Subject analysis sets

Subject analysis set title	AZD8601
Subject analysis set type	Safety analysis
Subject analysis set description: AZD8601	

Subject analysis set title	Placebo
Subject analysis set type	Safety analysis
Subject analysis set description:	
Placebo	
Subject analysis set title	AZD8601
Subject analysis set type	Full analysis
Subject analysis set description:	
AZD8601	
Subject analysis set title	Placebo
Subject analysis set type	Full analysis
Subject analysis set description:	
Placebo	

Reporting group values	AZD8601	Placebo	AZD8601
Number of subjects	7	4	7
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age Continuous Units: Years			
arithmetic mean	7		
standard deviation	±	±	±
Sex: Female, Male Units: Participants			
Female			
Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

Reporting group values	Placebo		
Number of subjects	4		
Age categorical Units: Subjects			
In utero			

Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age Continuous Units: Years arithmetic mean standard deviation	±		
Sex: Female, Male Units: Participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

## End points

### End points reporting groups

Reporting group title	AZD8601 3mg
Reporting group description: AZD8601 3mg	
Reporting group title	Placebo
Reporting group description: Placebo	
Subject analysis set title	AZD8601
Subject analysis set type	Safety analysis
Subject analysis set description: AZD8601	
Subject analysis set title	Placebo
Subject analysis set type	Safety analysis
Subject analysis set description: Placebo	
Subject analysis set title	AZD8601
Subject analysis set type	Full analysis
Subject analysis set description: AZD8601	
Subject analysis set title	Placebo
Subject analysis set type	Full analysis
Subject analysis set description: Placebo	

### Primary: Number of subjects with Adverse Events

End point title	Number of subjects with Adverse Events <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe: From dose to end of follow up	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Adverse events reported in Adverse Events section

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	4		
Units: Participants	7	4		

### Statistical analyses

No statistical analyses for this end point

### Primary: Pulse rate (vital sign)



End point title	Pulse rate (vital sign) <sup>[2]</sup>
End point description:	
End point type	Primary
End point timeframe:	
From dosing to end of follow up	
Notes:	
[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: Only summary statistics are available for safety endpoints.	

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	4		
Units: beats/min				
arithmetic mean (standard deviation)				
Baseline	63.1 (± 10.42)	62.6 (± 6.04)		
Day 1	81.3 (± 7.38)	75.2 (± 4.20)		
Day 2	85.2 (± 6.54)	81.1 (± 7.01)		
Day 3	83.6 (± 8.38)	82.4 (± 6.80)		
Day 4	81.9 (± 14.54)	75.3 (± 7.63)		
Visit 5 (Day 30)	74.3 (± 13.33)	65.5 (± 6.81)		
Visit 6 (Day 91)	66.9 (± 15.05)	70.8 (± 7.18)		
Visit 7 (Day 182)	63.6 (± 15.62)	61.0 (± 2.16)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of subjects with an ECG determined to be abnormal and clinically significant

End point title	Number of subjects with an ECG determined to be abnormal and clinically significant <sup>[3]</sup>
End point description:	
End point type	Primary
End point timeframe:	
Baseline to end of follow up	
Notes:	
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: Only summary statistics are available for safety endpoints.	

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	4		
Units: Participants				
Baseline	0	0		
End of treatment	1	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with high values of Leucocytes, Particle Concentration

End point title	Number of subjects with high values of Leucocytes, Particle Concentration <sup>[4]</sup>
-----------------	--

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	3	1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Oxygen saturation (vital sign)

End point title	Oxygen saturation (vital sign) <sup>[5]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From dosing to end of follow up

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	4		
Units: Percent				
arithmetic mean (standard deviation)				
Baseline	96.0 (± 0)	100.0 (± 0)		
Day 1	97.6 (± 4.46)	99.3 (± 0.80)		
Day 2	97.7 (± 1.68)	97.4 (± 2.42)		
Day 3	95.6 (± 2.14)	96.6 (± 3.60)		
Day 4	95.7 (± 1.85)	95.8 (± 3.74)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Systolic blood pressure (vital sign)

End point title	Systolic blood pressure (vital sign) <sup>[6]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From baseline to end of follow up

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	4		
Units: mmHg				
arithmetic mean (standard deviation)				
Baseline	141.4 (± 24.42)	141.7 (± 23.32)		
Day 1	113.5 (± 5.67)	116.8 (± 12.53)		
Day 2	118.1 (± 11.98)	104.8 (± 4.39)		
Day 3	118.5 (± 8.04)	100.8 (± 10.82)		
Day 4	129.1 (± 116.63)	109.0 (± 6.48)		
Visit 5 (Day 30)	135.9 (± 17.56)	134.5 (± 29.49)		
Visit 6 (Day 91)	146.3 (± 11.76)	163.0 (± 35.39)		
Visit 7 (Day 182)	142.3 (± 13.00)	147.3 (± 34.07)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects with high values of Erythrocytes, Particle Concentration

End point title	Number of subjects with high values of Erythrocytes, Particle Concentration <sup>[7]</sup>
-----------------	--

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up at 6 months.

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Diastolic blood pressure (vital sign)

End point title	Diastolic blood pressure (vital sign) <sup>[8]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From baseline to end of follow up

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	4		
Units: mmHg				
arithmetic mean (standard deviation)				
Baseline	82.1 (± 17.95)	74.5 (± 23.57)		
Day 1	59.2 (± 6.52)	62.0 (± 7.63)		
Day 2	59.2 (± 10.65)	58.0 (± 5.12)		

Day 3	63.7 (± 8.64)	56.9 (± 2.83)		
Day 4	73.7 (± 11.07)	66.8 (± 5.91)		
Visit 5 (Day 30)	78.1 (± 10.16)	83.5 (± 14.55)		
Visit 6 (Day 91)	80.0 (± 7.09)	93.8 (± 16.62)		
Visit 7 (Day 182)	79.4 (± 8.06)	83.5 (± 19.60)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Haemoglobin

End point title	Haemoglobin <sup>[9]</sup>
-----------------	----------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Erythrocyte, Volume Fraction

End point title	Erythrocyte, Volume Fraction <sup>[10]</sup>
-----------------	--

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Erythrocytes, Mean Cell Volume

End point title	Erythrocytes, Mean Cell Volume <sup>[11]</sup>
-----------------	--

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	4		
Units: Number of subjects				
Baseline	1	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Mean Cell Hemoglobin

End point title	Mean Cell Hemoglobin <sup>[12]</sup>
-----------------	--------------------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	4		
Units: Number of subjects				
Baseline	1	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Mean Cell Hemoglobin Conc.

End point title	Mean Cell Hemoglobin Conc. <sup>[13]</sup>
-----------------	--

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	3		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Neutrophils

End point title	Neutrophils <sup>[14]</sup>
-----------------	-----------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	2	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Monocytes

End point title	Monocytes <sup>[15]</sup>
-----------------	---------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Lymphocytes

End point title	Lymphocytes <sup>[16]</sup>
-----------------	-----------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.



End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Eosinophils

End point title	Eosinophils <sup>[17]</sup>
-----------------	-----------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Basophils

End point title	Basophils <sup>[18]</sup>
-----------------	---------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Platelets

End point title	Platelets <sup>[19]</sup>
-----------------	---------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Reticulocytes

End point title	Reticulocytes <sup>[20]</sup>
-----------------	-------------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	2		
Units: Number of subjects				
Baseline	1	1		
Maximum value during treatment	1	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Prothrombin Complex INR

End point title	Prothrombin Complex INR <sup>[21]</sup>
-----------------	---

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Activated Partial Thromboplastin Time

End point title	Activated Partial Thromboplastin Time <sup>[22]</sup>
-----------------	---

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Fibrinogen

End point title	Fibrinogen <sup>[23]</sup>
-----------------	----------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	3	3		

## Statistical analyses

No statistical analyses for this end point

### Primary: Sodium

End point title	Sodium <sup>[24]</sup>
-----------------	------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Potassium

End point title	Potassium <sup>[25]</sup>
-----------------	---------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Urea

End point title	Urea <sup>[26]</sup>
-----------------	----------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	4		
Units: Number of subjects				
Baseline	0	1		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Albumin

End point title	Albumin <sup>[27]</sup>
-----------------	-------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Creatinine

End point title	Creatinine <sup>[28]</sup>
-----------------	----------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	1	1		
Maximum value during treatment	1	1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Calcium

End point title	Calcium <sup>[29]</sup>
-----------------	-------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Phosphate

End point title	Phosphate <sup>[30]</sup>
-----------------	---------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Alkaline Phosphatase

End point title	Alkaline Phosphatase <sup>[31]</sup>
-----------------	--------------------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	1		
Maximum value during treatment	0	1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Aspartate Aminotransferase

End point title	Aspartate Aminotransferase <sup>[32]</sup>
-----------------	--

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.



End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	1	1		
Maximum value during treatment	0	1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Alanine Aminotransferase

End point title	Alanine Aminotransferase <sup>[33]</sup>
-----------------	--

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

End point values	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	1		
Maximum value during treatment	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Bilirubin, Total

End point title	Bilirubin, Total <sup>[34]</sup>
-----------------	----------------------------------

End point description:

Values are classified as high if they are above the normal reference range, based on local lab reference ranges.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to end of follow up

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics are available for safety endpoints.

<b>End point values</b>	AZD8601 3mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	5	4		
Units: Number of subjects				
Baseline	0	0		
Maximum value during treatment	1	0		

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events are summarized from the first dose of IP dose throughout the treatment period and including the follow-up period.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Reporting group title	AZD8601 3mg
-----------------------	-------------

Reporting group description:

AZD8601 3mg

Serious adverse events	Placebo	AZD8601 3mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 4 (25.00%)	3 / 7 (42.86%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Vascular graft occlusion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site impaired healing			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site inflammation			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Embolic cerebral infarction			

subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
Anaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coagulopathy			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin and subcutaneous tissue disorders</b>			
Skin necrosis			
subjects affected / exposed	1 / 4 (25.00%)	0 / 7 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Placebo	AZD8601 3mg	
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	4 / 4 (100.00%)	7 / 7 (100.00%)	
<b>Vascular disorders</b>			
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	
<b>General disorders and administration site conditions</b>			
Chest pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	
Feeling cold			
subjects affected / exposed	0 / 4 (0.00%)	1 / 7 (14.29%)	
occurrences (all)	0	1	
Non-cardiac chest pain			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p> <p>1 / 4 (25.00%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p> <p>0 / 7 (0.00%)</p> <p>0</p>	
<p>Reproductive system and breast disorders</p> <p>Gynaecomastia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 4 (0.00%)</p> <p>0</p>	<p>1 / 7 (14.29%)</p> <p>1</p>	
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Dyspnoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pleural effusion</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p> <p>2 / 4 (50.00%)</p> <p>2</p>	<p>1 / 7 (14.29%)</p> <p>1</p> <p>0 / 7 (0.00%)</p> <p>0</p>	
<p>Psychiatric disorders</p> <p>Insomnia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	
<p>Investigations</p> <p>Liver function test increased</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	
<p>Injury, poisoning and procedural complications</p> <p>Procedural pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 4 (25.00%)</p> <p>1</p>	<p>0 / 7 (0.00%)</p> <p>0</p>	
<p>Cardiac disorders</p> <p>Atrial fibrillation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Left ventricular dysfunction</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Sinus bradycardia</p>	<p>2 / 4 (50.00%)</p> <p>2</p> <p>0 / 4 (0.00%)</p> <p>0</p>	<p>2 / 7 (28.57%)</p> <p>2</p> <p>1 / 7 (14.29%)</p> <p>1</p>	

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Ventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Tachycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Ventricular arrhythmia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Nervous system disorders Syncope subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Embolitic cerebral infarction subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Dizziness subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	1 / 7 (14.29%) 1	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	2 / 4 (50.00%) 2	1 / 7 (14.29%) 1	
Coagulopathy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Eye disorders Cataract subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Gastrointestinal disorders			

Nausea subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Dyspepsia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	1 / 7 (14.29%) 1	
Myalgia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 7 (0.00%) 0	
Infections and infestations Wound infection subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 7 (0.00%) 0	
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 7 (0.00%) 0	
Metabolism and nutrition disorders Dyslipidaemia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 7 (0.00%) 0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 February 2018	<p>Number of countries updated to reflect the current situation where the study initially will be conducted in 1 country but with the possibility to expand to further countries. Change to Lead Investigator and their designation.</p> <p>Correction to Visit 1 time window to earliest 3 months and latest 15 days before surgery (Day - 90 to -15). Clarification that Visit 3 is from Day from -1 to 4.</p> <p>Inclusion criterion 4 corrected to "Indication for elective CABG surgery enrolled at least 15 days before the planned surgery."</p> <p>Table 1 updated with assessments that were identified as incorrect or missing in Table compared to text.</p> <p>Table 1 of CSP, Text updated to allow Visit 1 and Visit 2 on the same day except for the PET assessment.</p>
08 May 2018	<p>Table 1 of CSP modification of timepoints for several assessments or sample collections. Removed optional nature of LAD CFVR.</p> <p>Updated text for SAE reporting.</p>
22 January 2019	<p>Adjustment to text regarding number of sites and study timelines in synopsis and Section 1.4. Other administrative changes.</p> <p>Time window between Visit 2 and Visit 3 adjusted.</p> <p>Exploratory gyrocardiography assessment was removed from the study protocol.</p> <p>AZ activity app for the digital 6-min walk test was not applicable for the newly added country Germany but remained optional in other participating countries.</p> <p>Minor adjustments made to urinalysis.</p> <p>CSP adjusted to allow patients to be enrolled at one site and, if needed, to perform the 150 PET assessment at another, named site.</p> <p>Table 1, for blood pressure and pulse oximetry number of assessments on Day 1 corrected from 4 to 3.</p>



27 February 2020	<p>Expected study duration extended to Q1 2022 in the Synopsis.</p> <p>Local ethics committee requested that the safety review procedure included external experts.</p> <p>Study specific stopping criteria added.</p> <p>An unblinded DMG was added.</p> <p>Added that if a patient was referred to another hospital for the 150 PET assessment, CT could also be performed there.</p>
------------------	---

Notes:

---

## Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported